Recent news
August 2011
IDRI, USAID launch new partnership to develop a malaria vaccine
August 17, 2011 -- The Infectious Disease Research Institute (IDRI) has announced a new collaboration with the US Agency for International Development (USAID), focused on support for work with the Walter Reed Army Institute of Research (WRAIR) to develop a new vaccine against malaria. The collaboration is for the development of a novel malaria vaccine, which combines WRAIR’s malaria antigen CelTOS with IDRI’s potent GLA-SE adjuvant.
“The collaboration with WRAIR illustrates again the broad utility of GLA-SE as a vaccine adjuvant,” said Steven G. Reed, IDRI’s founder, president and chief scientific officer. “We are very excited to be moving this important project ahead and particularly pleased with the validating interest from USAID.” Col. Christian Ockenhouse, director of WRAIRs’ Malaria Vaccine Development Program, said, “The Walter Reed Army Institute of Research is pleased that both IDRI and USAID have partnered with us in helping support the development of malaria vaccines to prevent infection in children worldwide and to protect our men and women serving in uniform in areas of the world where malaria is still a major infectious disease.” See the press release below for more details.
